Renal interstitial fibrosis induced by high-dose mesoporous silica nanoparticles via the NF-κB signaling pathway

International Journal of Nanomedicine

Volumn 10, Issue , 2014, Pages 1-22

  Chen, Xi ^a,b   Zhouhua, Wang ^a   Jie, Zhou ^a   Xinlu, Fu ^a   Jinqiang, Liang ^a   Yuwen, Qiu ^a   Zhiying, Huang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Acute kidney injury; Mesoporous silica nanoparticles (MSNs); NF B; Renal interstitial fbrosis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESOPOROUS SILICA NANOPARTICLE; SILICA NANOPARTICLE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; INTERLEUKIN 1BETA; INTERLEUKIN 6; NANOPARTICLE; SILICON DIOXIDE; TUMOR NECROSIS FACTOR;

ACUTE KIDNEY FAILURE; ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY TEST; FEMALE; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY HOMOGENATE; KIDNEY PARENCHYMA; MOUSE; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE REGENERATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; GENETICS; INFLAMMATION; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; RAT;

ANIMALIA; MUS; RATTUS;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROSIS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; KIDNEY; KIDNEY DISEASES; MICE; MICE, INBRED BALB C; NANOPARTICLES; NF-KAPPA B; RATS; SIGNAL TRANSDUCTION; SILICON DIOXIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84933500229     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S73538     Document Type: Article

References (63)

1. Vallhov H, Gabrielsson S, Strømme M, Scheynius A, Garcia-Bennett AE. Mesoporous silica particles induce size dependent effects on human dendritic cells. Nano Lett. 2007;7(12):3576–3582.
2. Chung TH, Wu SH, Ya o M, et al. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials. 2007; 28(19):2959–2966.
3. Carino IS, Pasqua L, Testa F, et al. Silica-based mesoporous materials as drug delivery system for methotrexate release. Drug Deliv. 2007;14(8):491–495.
4. Gu J, Fan W, Shimojima A, Okubo T. Organic-inorganic mesoporous nanocarriers integrated with biogenic ligands. Small. 2007;3(10): 1740–1744.
5. Yun HS, Park JW, Kim SH, Kim YJ, Jang JH. Effect of the pore structure of bioactive glass balls on biocompatibility in vitro and in vivo. Acta Biomater. 2011;7(6):2651–2660.
6. Cainelli F, Tanko MN, Vento S. Vento, Silica exposure and silicosis: action is needed now. South Med J. 2010;103(11):1078.
7. DeMuth P, Hurley M, Wu C, et al. Mesoscale porous silica as drug delivery vehicles: Synthesis, characterization, and pH-sensitive release profiles. Microporous and Mesoporous Materials. 2011;141(1): 128–134.
8. Yuan L, Tang Q, Yang D, Zhang JZ, Zhang F, Hu J. Preparation of pH-responsive mesoporous silica nanoparticles and their application in controlled drug delivery. The Journal of Physical Chemistry C. 2011; 115(20):7.
9. Wang T, Chai F, Fu Q, et al. Uniform hollow mesoporous silica nano-cages for drug delivery in vitroand in vivo for liver cancer therapy. Journal of Materials Chemistry. 2011;21(14):5299–5306.
10. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharma-cokinetics and biocompatibility. Journal of Materials Chemistry. 2011;21(16):5845–5855.
11. Lee S, Yun HS, Kim SH. The comparative effects of mesoporous silica nanoparticles and colloidal silica on infammation and apoptosis. Bio-materials. 2011;32(35):9434–9443.
12. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, Biodis-tribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals. Small. 2010;6(16): 1794–1805.
13. Yu T, Greish K, McGill LD, Ray A, Ghandehari H. Infuence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. ACS Nano. 2012;6(3):2289–2301.
14. Wang F, Gao F, Lan M, Yuan H, Huang Y, Liu J. Oxidative stress contributes to silica nanoparticle-induced cytotoxicity in human embryonic kidney cells. Toxicol In Vitro. 2009;23(5):808–815.
15. Passagne I, Morille M, Rousset M, Pujalté I, L’azou B. Implication of oxidative stress in size-dependent toxicity of silica nanoparticles in kidney cells. Toxicology. 2012;299(2–3):112–124.
16. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621–663.
17. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001;50(12):2792–2808.
18. Rial NS, Choi K, Nguyen T, Snyder B, Slepian MJ. Nuclear factor kap-paB (NF-κB): a novel cause for diabetes, coronary artery disease and cancer initiation and promotion? Med Hypotheses. 2012;78(1):29–32.
19. Schmid H, Boucherot A, Yasuda Y, et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes. 2006;55(11):2993–3003.
20. Li L, Tang F, Liu H, et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano. 2010;4(11):6874–6882.
21. Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small. 2007; 3(8):1341–1346.
22. Wang QX, Xiang Y, Cui YL, Lin KM, Zhang XF. Dietary blue pigments derived from genipin, attenuate infammation by inhibiting LPS-induced iNOS and COX-2expression via the NF-κB inactivation. PLoS One. 2012;7(3):e34112.
23. Zhang JY, Jin H, Wang GF, et al. Methyl-1-hydroxy-2-naphthoate, a novel naphthol derivative, inhibits lipopolysaccharide-induced infam-matory response in macrophages via suppression of NF-κB, JNK and p38 MAPK pathways. Infamm Res. 2011;60(9):851–859.
24. Wang LY, Wang HY, Ouyang J, et al. Low concentration of lipopoly-saccharide acts on MC3T3-E1 osteoblasts and induces proliferation via the COX-2-independent NFkappaB pathway. Cell Biochem Funct. 2009;27(4):238–242.
25. Liu H, Chen D, Li L, et al. Multifunctional gold nanoshells on silica nanorattles: a platform for the combination of photothermal therapy and chemotherapy with low systemic toxicity. Angew Chem Int Ed Engl. 2011;50(4):891–895.
26. Hamilton RF Jr, Thakur SA, Mayfair JK, Holian A. MARCO mediates silica uptake and toxicity in alveolar macrophages from C57BL/6 mice. J Biol Chem. 2006;281(45):34218–3426.
27. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278–1288.
28. Slowing II, Wu CW, Vivero-Escoto JL, Lin VS. Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. Small. 2009;5(1):57–62.
29. Tao Z, Morrow MP, Asefa T, et al. Mesoporous silica nanoparticles inhibit cellular respiration. Nano Lett. 2008;8(5):1517–1526.
30. Bellusci M, La Barbera A, Padella F, et al. Biodistribution and acute toxicity of a nanofuid containing manganese iron oxide nanoparticles produced by a mechanochemical process. Int J Nanomedicine. 2014;9:1919–1929.
31. Mancuso L, Cao G. Acute toxicity test of CuO nanoparticles using human mesenchymal stem cells. Toxicol Mech Methods. 2014;24(7): 449–554.
32. Lorke D. A new approach to practical acute toxicity testing. Arch Toxicol. 1983;54(4):275–287.
33. International conference on harmonisation. ICH guidance on toxicoki-netics: the assessment of systemic exposure in toxicity studies s3a; 1994. Available from: http://www.ich.org/fleadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S3A/Step4/S3A_Guideline.pdf. Accessed November 15, 2014.
34. The Organisation for Economic Co-operation and Development. OECD guidelines for the testing of the chemicals-draft proposal for a revised TG 417: Toxicokinetics; 2008. Available from: http://www.oecd.org/chemicalsafety/testing/41690691.pdf. Accessed November 15, 2014.
35. United States Food and Drug Administration. M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals; 2010. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm073246.pdf. Accessed November 15, 2014.
36. United States Food and Drug Administration. Guidance for industry, developing medical imaging drug and biological products, part 1: conducting safety assessments; 2004. Available from: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071600.pdf. Accessed November 15, 2014.
37. Kanakia S, Toussaint JD, Mullick Chowdhury S, et al. Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulations. Biomaterials. 2014;35(25):7022–7031.
38. Eddy AA. Molecular basis of renal fbrosis. Pediatr Nephrol. 2000; 15(3–4):290–301.
39. Leung KC, Tonelli M, James MT. Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol. 2013;9(2): 77–85.
40. Souris JS, Lee CH, Cheng SH, et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomateri-als. 2010;31(21):5564–5574.
41. Nabeshi H, Yoshikawa T, Matsuyama K, et al. Systemic distribution, nuclear entry and cytotoxicity of amorphous nanosilica following topical application. Biomaterials. 2011;32(11):2713–2724.
42. Nabeshi H, Yoshikawa T, Matsuyama K, et al. Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. Nanotech-nology. 2012;23(4):045101.
43. Yoshida T, Yoshioka Y, Tochigi S, et al. Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice. Part Fibre Toxicol. 2013;10:41.
44. Liu T, Li L, Fu C, Liu H, Chen D, Tang F. Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles. Biomaterials. 2012;33(7):2399–2407.
45. Tao Z, Toms BB, Goodisman J, Asefa T. Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials. Chem Res Toxicol. 2009;22(11):1869–1880.
46. Sun W, Fang N, Trewyn BG, et al. Endocytosis of a single mesoporous silica nanoparticle into a human lung cancer cell observed by differential interference contrast microscopy. Anal Bioanal Chem. 2008; 391(6):2119–2125.
47. Harrison J, Chen JQ, Miller W, et al. Risk of silicosis in cohorts of Chinese tin and tungsten miners and pottery workers (II): Workplace-specific silica particle surface composition. Am J Ind Med. 2005; 48(1):10–15.
48. Mundt KA, Birk T, Parsons W, et al. Respirable crystalline silica exposure-response evaluation of silicosis morbidity and lung cancer mortality in the German porcelain industry cohort. J Occup Environ Med. 2011;53(3):282–289.
49. Mühlfeld C, Gehr P, Rothen-Rutishauser B. Translocation and cellular entering mechanisms of nanoparticles in the respiratory tract. Swiss Med Wkly. 2008;138(27–28):387–391.
50. Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005;113(7):823–839.
51. Guijarro C, Egido J. Transcription factor-kappaB (NF-kappaB) and renal disease. Kidney Int. 2001;59(2):415–424.
52. Bitzer M, von Gersdorff G, Liang D, et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappaB/RelA. Genes Dev. 2000;14(2):187–197.
53. Chen L, Zhang J, Zhang Y, Wang Y, Wang B. Improvement of infam-matory responses associated with NF-kappaB pathway in kidneys from diabetic rats. Infamm Res. 2008;57(5):199–204.
54. Ghiazza M, Polimeni M, Fenoglio I, Gazzano E, Ghigo D, Fubini B. Does vitreous silica contradict the toxicity of the crystalline silica paradigm? Chem Res Toxicol. 2010;23(3):620–629.
55. Kang JL, Jung HJ, Lee K, Kim HR. Src tyrosine kinases mediate crystalline silica-induced NF-kappaB activation through tyrosine phosphorylation of IkappaB-alpha and p65 NF-kappaB in RAW 264.7 macrophages. Toxicol Sci. 2006;90(2):470–477.
56. Mirza A, Liu SL, Frizell E, et al. A role for tissue transglutaminase in hepatic injury and fbrogenesis, and its regulation by NF-kappaB. Am J Physiol. 1997;272(2 Pt 1):G281–G288.
57. Bondar’ IA, Klimontov VV, Nadeev AP. [Urinary excretion of proinfammatory cytokines and transforming growth factor beta at early stages of diabetic nephropathy]. Ter Arkh. 2008;80(1):52–56. Russian.
58. Iwamoto M, Mizuiri S, Arita M, Hemmi H. Nuclear factor-kappaB activation in diabetic rat kidney: evidence for involvement of P-selectin in diabetic nephropathy. Tohoku J Exp Med. 2005;206(2):163–171.
59. Mezzano S, Aros C, Droguett A, et al. NF-kappaB activation and over-expression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant. 2004;19(10):2505–2512.
60. Huang X, Zhuang J, Teng X, et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials. 2010;31(24):6142–2153.
61. Huang X, Teng X, Chen D, Tang F, He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials. 2010;31(3):438–448.
62. Angelos SL, Liong M, Choi E, Zink JI. Mesoporous silicate materials as substrates for molecular machines and drug delivery. Chemical Engineering Journal. 2008;137:4–13.
63. Huang X, Zhuang J, Chen D, et al. General strategy for designing functionalized magnetic microspheres for different bioapplications. Langmuir. 2009;25(19):11657–11663.